Cancer cells restrict immunogenicity of retrotransposon expression via distinct mechanisms

癌细胞通过不同的机制限制逆转录转座子表达的免疫原性。

阅读:3
作者:Siyu Sun,Eunae You,Jungeui Hong,David Hoyos,Isabella Del Priore,Kaloyan M Tsanov,Om Mattagajasingh,Andrea Di Gioacchino,Sajid A Marhon,Jonathan Chacon-Barahona,Hao Li,Hua Jiang,Samira Hozeifi,Omar Rosas-Bringas,Katherine H Xu,Yuhui Song,Evan R Lang,Alexandra S Rojas,Linda T Nieman,Bidish K Patel,Rajmohan Murali,Pharto Chanda,Ali Karacay,Nicolas Vabret,Daniel D De Carvalho,Daniel Zenklusen,John LaCava,Scott W Lowe,David T Ting,Christine A Iacobuzio-Donahue,Alexander Solovyov,Benjamin D Greenbaum

Abstract

To thrive, cancer cells must navigate acute inflammatory signaling accompanying oncogenic transformation, such as via overexpression of repeat elements. We examined the relationship between immunostimulatory repeat expression, tumor evolution, and the tumor-immune microenvironment. Integration of multimodal data from a cohort of pancreatic ductal adenocarcinoma (PDAC) patients revealed expression of specific Alu repeats predicted to form double-stranded RNAs (dsRNAs) and trigger retinoic-acid-inducible gene I (RIG-I)-like-receptor (RLR)-associated type-I interferon (IFN) signaling. Such Alu-derived dsRNAs also anti-correlated with pro-tumorigenic macrophage infiltration in late stage tumors. We defined two complementary pathways whereby PDAC may adapt to such anti-tumorigenic signaling. In mutant TP53 tumors, ORF1p from long interspersed nuclear element (LINE)-1 preferentially binds Alus and decreases their expression, whereas adenosine deaminases acting on RNA 1 (ADAR1) editing primarily reduces dsRNA formation in wild-type TP53 tumors. Depletion of either LINE-1 ORF1p or ADAR1 reduced tumor growth in vitro. The fact that tumors utilize multiple pathways to mitigate immunostimulatory repeats implies the stress from their expression is a fundamental phenomenon to which PDAC, and likely other tumors, adapt.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。